Soleno Therapeutics, Inc. - Common Stock (SLNO)

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

The companies are working on treatments for a rare, genetic disease that can cause excessive hunger.

Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal.

Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch.

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.